Gender representation in trials

Controlled Clinical Trials

Volumn 21, Issue 5, 2000, Pages 462-475

  Meinert, Curtis L ^a   Gilpin, Adele Kaplan ^a   Ünalp, Aynur ^a   Dawson, Christopher ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bias; Clinical research; Clinical trials; Gender; Legislation; Women's health

Indexed keywords

ARTICLE; CLINICAL TRIAL; DATA BASE; FEMALE; GENDER; HEALTH; LAW; MALE; MEDICAL INFORMATION; MEDICAL LITERATURE;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; FEMALE; HUMANS; MALE; SEX DISTRIBUTION;

EID: 0033833111     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00086-6     Document Type: Article

References (33)

1. Women and Health Research. Ethical and Legal Issues of Including Women in Clinical Studies:1994;National Academy Press, Washington, DC.
2. Women and Health Research. Ethical and Legal Issues of Including Women in Clinical Studies, Workshop and Commissioned Papers:1994;National Academy Press, Washington, DC.
3. Rowbotham S. Women in Movement. Feminism and Social Action:1992;Routledge, New York.
4. NIH Guide for Grants and Contracts. 1986 (24 October); 15(22).
5. United States General Accounting Office. Statement of Mark V Nadel before Subcommittee on Housing and Consumer Interest Select Committee on Aging, House of Representatives. Washington, DC: GAO; 24 July 1990.
6. United States General Accounting Office. Women's Health: FDA Needs to Ensure More Study of Gender Differences in Prescription Drug Testing. Washington, DC: GAO/HRD-93-17; 1992.
7. Caschetta M.B., Chavkin W., McGovern T. FDA policy on women in drug trials. N Engl J Med. 329:1993;1815-1816.
8. Merkatz R.B., Temple R., Sobel S., Feiden Kessler D.A., the Working Group on Women in Clinical Trials Women in clinical trials of new drugs. A change in Food and Drug Administration policy N Engl J Med. 329:1993;292-296.
9. The Coronary Drug Project. Design, methods, and baseline results Circulation. 47(Suppl 1):1973;I1-I50.
10. The Coronary Drug Project. Initial findings leading to modifications of its research protocol JAMA. 214:1970;1303-1313.
11. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine JAMA. 220:1972;996-1008.
12. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg/day estrogen group JAMA. 226:1973;652-657.
13. The Coronary Drug Project. Clofibrate and niacin in coronary heart disease JAMA. 231:1975;360-381.
14. Recruitment for clinical trials - The Lipid Research Clinics Coronary Primary Prevention Trial experience. Its implications for future trials Circulation. 66(Suppl):1982;IV1-IV78.
15. The Lipid Research Clinics Coronary Primary Prevention Trial results. JAMA. 251:1984;351-364.
16. Statistical design considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J Chronic Dis. 30:1977;261-275.
17. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. JAMA. 248:1982;1465-1477.
18. Hennekens C.H., Eberlein K., for the Physician's Health Study Research Group A randomized trial of aspirin and β-carotene among U.S. physicians. Preventive Med. 14:1985;165-168.
19. Hennekens C.H., Buring J.E. Methodologic considerations in the design and conduct of randomized trials. The U.S. Physicians' Health Study Control Clin Trials. 10:1989;142S-150S.
20. Final report on the aspirin component of the ongoing Physician's Health Study. N Engl J Med. 321:1989;129-135.
21. Manson J.E., Satterfield S., Buring J.E., Hennekens C.H. Baseline characteristics of participants in the Physicians' Health Study. A randomized trial of aspirin and beta-carotene in U.S. Physicians Am J Prev Med. 7:1991;150-154.
22. Ridker P.M., Manson J.E., Gaziano J.M., Buring J.E., Hennekens C.H. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial Ann Intern Med. 114:1991;835-839.
23. The National Commission for the Protection of Human Subjects of Biomedical Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. DHEW pub no. (OS) 78-0012, Appendix I, DHEW pub no (OS) 78-0013, Appendix II, DHEW pub (OS) 78-0014, Washington, DC, 1978.
24. NIH Advisory Committee on Women's Health Issues. Women's Health Issues Research Report: FY 1985-1987. Department of Health and Human Services, National Institutes of Health: Bethesda; 1989.
25. National Institutes of Health Revitalization Act of 1993. §131, Pub L No 103-43, 107 Stat 133 (codified at 42 USC §289a-2).
26. National Institutes of Health Department of Health and Human Services. NIH Guidelines on the inclusion of women and minorities as subjects in clinical research. Federal Register 1994;59:14508-14513.
27. Freedman L.S., Simon R., Foulkes M.A.et al. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 - The perspective of NIH clinical trialists (with discussion and response). Control Clin Trials. 16:1995;277-312.
28. National Library of Medicine, PubMed web site, MeSH browser; http://www.ncbi.nlm.nih.gov .
29. Meinert CL, Gilpin AK. Estimation of gender bias in clinical trials. Stat Med (in press).
30. Meinert CL. Clinical Trials Dictionary: Terminology and Usage Recommendations. The Johns Hopkins Center for Clinical Trials: Baltimore; 1996.
31. National Center for Health Statistics. Health, United States, 1995. U.S. Public Health Service , DHHS Pub No (PHS) 96-1232, Hyattsville, MD, May 1996 (Table 37, pp. 126-128).
32. Helmuth L. Reports see progress, problems, in trials. Science. 288:2000;1562-1563.
33. National Institutes of Health. NIH Inventory of Clinical Trials: Fiscal Year 1979 (unpublished). Division of Research Grants, Bethesda, MD; 1980.